Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Characteristics of US adults with the metabolic syndrome and therapeutic implications.

Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, Gause D, Varas C, Ballantyne CM.

Diabetes Obes Metab. 2004 Sep;6(5):353-62.

PMID:
15287928
3.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
4.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

5.
6.

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.

Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group..

Diabetes Obes Metab. 2005 Jul;7(4):430-8. Erratum in: Diabetes Obes Metab. 2005 Jul;7(4):460.

PMID:
15955130
7.

The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.

Ito MK.

Ann Pharmacother. 2004 Feb;38(2):277-85. Review.

PMID:
14742767
8.
9.

Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.

Ucar E, Huzmeli C, Guven O, Savas N, Gullu M, Asilyoruk S, Kuvandik C, Temizkan A, Kuvandik G.

Ren Fail. 2009;31(3):221-8. doi: 10.1080/08860220802669883.

PMID:
19288328
10.

Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia.

Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT.

Diabetes Care. 2004 Apr;27(4):978-83.

PMID:
15047659
11.

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.

Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, Watson KE, Willey VJ, Stanek EJ.

Circulation. 2005 Feb 1;111(4):488-93.

12.

Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.

Gündogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A, Altunbas H, Gökce C, Kalkan A, Yazici C.

Metab Syndr Relat Disord. 2009 Oct;7(5):427-34. doi: 10.1089/met.2008.0068.

PMID:
19754305
13.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192
14.

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).

Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V, Grundy SM.

Am J Cardiol. 2005 Jan 15;95(2):194-8.

PMID:
15642551
15.

Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy).

Gurrola-Díaz CM, García-López PM, Sánchez-Enríquez S, Troyo-Sanromán R, Andrade-González I, Gómez-Leyva JF.

Phytomedicine. 2010 Jun;17(7):500-5. doi: 10.1016/j.phymed.2009.10.014.

PMID:
19962289
16.
17.
18.

Application of three-dimensional body scanner: observation of prevalence of metabolic syndrome.

Lin JD, Chiou WK, Weng HF, Fang JT, Liu TH.

Clin Nutr. 2004 Dec;23(6):1313-23.

PMID:
15556253
19.

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2005 Dec;21(12):1997-2006.

PMID:
16368051
20.

[The prevalence of metabolic syndrome in middle-aged in Kaunas population].

Gustiene O, Slapikas R, Klumbiene J, Sakalauskiene G, Kubilius R, Bagdzeviciūte S, Zaliūnas R.

Medicina (Kaunas). 2005;41(10):867-76. Lithuanian.

Items per page

Supplemental Content

Support Center